Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis

Clinical Infectious Diseases

Volumn 48, Issue 5, 2009, Pages 598-605

  Koo, Hoonmo L ^a,b   Koo, Diana C ^b   Musher, Daniel M ^a,d   Dupont, Herbert L ^a,b,c,e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CODEINE; DIPHENOXYLATE; LOPERAMIDE; METRONIDAZOLE; OPIATE DERIVATIVE; VANCOMYCIN; ANTIDIARRHEAL AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON DILATATION; DISEASE SEVERITY; DRUG INDICATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG EFFECT; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; ANTIDIARRHEALS; CLOSTRIDIUM DIFFICILE; COLITIS; DIARRHEA; HUMANS; TREATMENT OUTCOME;

EID: 60549085840     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596711     Document Type: Review

References (65)

1. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5:40-8.
2. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M; Canadian Hospital Epidemiology Committee. Canadian Nosocomial Infection Surveillance Program. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002; 23:137-40.
3. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004; 189:1585-9.
4. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:409-15.
5. Musher DM, Aslam S. Clostridium difficile disease. In: Scheld MW, Hammer SM, Hughes JM, eds. Emerging Infections 8. Washington, DC: American Society of Microbiology, 2008:313-35.
6. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-90.
7. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
8. Louie T, Gerson M, Grimard D, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD) [abstract 425a]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.
9. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102:2781-8.
10. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5:549-57.
11. Nair S, Yadav D, Corpuz M, Pitchumoni CS. Clostridium difficile colitis: factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol 1998; 93:1873-6.
12. Fekety R, Silva J, Armstrong J, et al. Treatment of antibiotic-associated enterocolitis with vancomycin. Rev Infect Dis 1981; 3(Suppl):S273-81.
13. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13:1417-9.
14. Wysowski DK. Increase in deaths related to enterocolitis due to Clostridium difficile in the United States, 1999-2002. Public Health Rep 2006; 121:361-2.
15. Deaths involving MRSA and Clostridium difficile continue to rise. Health Stat Q 2007:1-3.
16. Sprinz H. Pathogenesis of intestinal infections. Arch Pathol 1969; 87:556-62.
17. Formal SB, Abrams GD, Schneider H, Sprinz H. Experimental Shigella infections. VI. Role of the small intestine in an experimental infection in guinea pigs. J Bacteriol 1963; 85:119-25.
18. Kent TH, Formal SB, Labrec EH. Acute enteritis due to Salmonella typhimurium in opium-treated guinea pigs. Arch Pathol 1966; 81:501-8.
19. DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226:1525-8.
20. Janssen Pharmaceutica. Imodium US prescribing information. Available at: http://www.fda.gov/medwatch/SAFETY/2005/safety.htm. Accessed 24 April 2008.
21. Brown CH, Ferrante WA, Davis WD Jr. Toxic dilatation of the colon complicating pseudomembranous enterocolitis. Am J Dig Dis 1968; 13:813-21.
22. Cohen LE, Smith CJ, Pister JD, Wells RF. Clindamycin (Cleocin) colitis. Am J Roentgenol Radium Ther Nucl Med 1974; 121:301-4.
23. Keeffe EB, Katon RM, Chan TT, Melnyk CS, Benson JA Jr. Pseudomembranous enterocolitis: resurgence related to newer antibiotic therapy. West J Med 1974; 121:462-72.
24. Tully TE, Feinberg SB. A reappearance of antibiotic-induced pseudomembranous enterocolitis. Radiology 1974; 110:563-7.
25. Wettach GE. Pseudomembranous colitis after the prophylactic use of clindamycin. Arch Otolaryngol 1974; 100:246.
26. Axelrod M, Allon O, Felton M, Goldfinger M. Clindamycin-associated colitis with toxic megacolon. JAMA 1975; 233:419-20.
27. Gibson GE, Rowland R, Hecker R. Diarrhoea and colitis associated with antibiotic treatment. Aust N Z J Med 1975; 5:340-7.
28. Tedesco FJ, Anderson CB, Ballinger WF. Drug-induced colitis mimicking an acute surgical condition of the abdomen. Arch Surg 1975; 110:481-4.
29. Boyd WC, DenBesten L. Subtotal colectomy for refractory pseudomembranous enterocolitis. JAMA 1976; 235:181.
30. Hoogland T, Cooperman AM, Farmer RG, Fazio VW. Toxic megacolon - unusual complication of pseudomembranous colitis. Cleve Clin Q 1977; 44:149-55.
31. Schnitt SJ, Antonioli DA, Goldman H. Massive mural edema in severe pseudomembranous colitis. Arch Pathol Lab Med 1983; 107:211-3.
32. Burke GW, Wilson ME, Mehrez IO. Absence of diarrhea in toxic megacolon complicating Clostridium difficile pseudomembranous colitis. Am J Gastroenterol 1988; 83:304-7.
33. Walley T, Milson D. Loperamide related toxic megacolon in Clostridium difficile colitis. Postgrad Med J 1990; 66:582.
34. Beaugerie L, Ngô Y, Goujard F, et al. Etiology and management of toxic megacolon in patients with human immunodeficiency virus infection. Gastroenterology 1994; 107:858-63.
35. Snowden JA, Young MJ, McKendrick MW. Dilatation of the colon complicating acute self-limited colitis. Q J Med 1994; 87:55-62.
36. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36:673-9.
37. Resnik E, Lefevre CA. Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Int J Gynecol Cancer 1999; 9:512-4.
38. Kato H, Kato H, Nakamura M, Nakamura A. A case of toxic megacolon secondary to Clostridium difficile-associated diarrhea worsened after administration of an antimotility agent and molecular analysis of recovered isolates. J Gastroenterol 2007; 42:507-8.
39. Trudel JL, Deschênes M, Mayrand S, Barkun AN. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum 1995; 38:1033-8.
40. Goldberg HI. The barium enema and toxic megacolon: cause-effect relationship? Gastroenterology 1975; 68:617-8.
41. Novak E, Lee JG, Seckman CE, Phillips JP, DiSanto AR. Unfavorable effect of atropine-diphenoxylate (Lomotil) therapy in lincomycin-caused diarrhea. JAMA 1976; 235:1451-4.
42. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18:247-63.
43. Savidge TC, Pan WH, Newman P, O'Brien M, Anton PM, Pothoulakis C. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 2003; 125:413-20.
44. Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect 2001; 7:421-7.
45. Mogg GA, Keighley MR, Burdon DW, et al. Antibiotic-associated colitis - a review of 66 cases. Br J Surg 1979; 66:738-42.
46. Halsey J. Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 2008; 65:705-15.
47. Berman L, Carling T, Fitzgerald TN, et al. Defining surgical therapy for pseudomembranous colitis with toxic megacolon. J Clin Gastroenterol 2008; 42:476-80.
48. Bergström T, Alestig K, Thorén K, Trollfors B. Symptomatic treatment of acute infectious diarrhoea: loperamide versus placebo in a double-blind trial. J Infect 1986; 12:35-8.
49. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1):S32-42.
50. DuPont HL, Flores Sanchez J, Ericsson CD, et al. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med 1990; 88:15S-9S.
51. Johnson PC, Ericsson CD, DuPont HL, Morgan DR, Bitsura JA, Wood LV. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea. JAMA 1986; 255:757-60.
52. DuPont HL, Ericsson CD, DuPont MW, Cruz Luna A, Mathewson JJ. A randomized, open-label comparison of nonprescription loperamide and attapulgite in the symptomatic treatment of acute diarrhea. Am J Med 1990; 88:20S-3S.
53. Ericsson CD, DuPont HL, Mathewson JJ. Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler's diarrhea. J Travel Med 1997; 4:3-7.
54. Ericsson CD, DuPont HL, Mathewson JJ. Optimal dosing of ofloxacin with loperamide in the treatment of non-dysenteric travelers' diarrhea. J Travel Med 2001; 8:207-9.
55. DuPont HL, Jiang ZD, Belkind-Gerson J, et al. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007; 5:451-6.
56. Ericsson CD, DuPont HL, Okhuysen PC, Jiang ZD, DuPont MW. Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. J Travel Med 2007; 14:312-9.
57. Ericsson CD, Nicholls-Vasquez I, DuPont HL, Mathewson JJ. Optimal dosing of trimethoprim-sulfamethoxazole when used with loperamide to treat traveler's diarrhea. Antimicrob Agents Chemother 1992; 36:2821-4.
58. van Loon FP, Bennish ML, Speelman P, Butler C. Double blind trial of loperamide for treating acute watery diarrhoea in expatriates in Bangladesh. Gut 1989; 30:492-5.
59. Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med 1993; 118:582-6.
60. Ramage JK, Miller AR, Clarke PD. Acute diarrhoea in expatriates in Bangladesh. Gut 1990; 31:123.
61. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.
62. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1):S12-8.
63. Triadafilopoulos G, Hallstone AE. Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology 1991; 101:685-91.
64. Bolton RP, Read AE. Clostridium difficile in toxic megacolon complicating acute inflammatory bowel disease. Br Med J (Clin Res Ed) 1982; 285:475-6.
65. Hoberman LJ, Eigenbrodt EH, Kilman WJ, Hughes LR, Norgaard RP, Fordtran JS. Colitis associated with oral clindamycin therapy: a clinical study of 16 patients. Am J Dig Dis 1976; 21:1-17.